AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Subscribe To Our Newsletter & Stay Updated